https://www.selleckchem.com/pr....oducts/4-phenylbutyr
In-hospital mortality was observed for 33 RAAS inhibitor users (9%) and 51 nonusers (3%) (p less then 0.001). However, after adjustment for age, sex, Charlson Comorbidity Index, immunosuppression, and hospital type, the use of RAAS inhibitors was not associated with a higher risk of mortality (adjusted OR, 0.88; 95% confidence interval, 0.53-1.44; p=0.6. No significant differences were observed between RAAS inhibitor users and nonusers in terms of vasopressor use, modes of ventilation, extracorporeal membrane oxyge
Like
Comment
Share
